Ziding Feng

Headshot photo of Ziding Feng
Affiliate Professor
Biostatistics
Co-Program Head Biostatistics
Fred Hutchinson Cancer Research Center
Member Public Health Sciences Division
Fred Hutchinson Cancer Research Center
PhD
Biometry
Cornell University
1990
MS
Entomology
Cornell University
1985
BS
Plant Protection
Nanjing Agricultural University
1982

Ziding Feng is a biometrics expert who applies statistical analysis to biological data. Much of his research is focused on biomarker evaluation for cancer risk assessment, early detection, diagnosis and prognosis. For many years, he was principal investigator of the Data Management and Coordinating Center for the National Cancer Institute-funded Early Detection Research Network, or EDRN, a multicenter research collaboration that focuses on biomarker discovery and validation. In that role, he was responsible for coordinating all of EDRN’s research activities, providing logistical support and conducting statistical and computational research for data analysis. Dr. Feng has also acted as lead biostatistician on a number of large, multicenter biomarker trials for cancers of the prostate, liver, lung, colon and esophagus. 

PhD
Biometry
Cornell University
1990
MS
Entomology
Cornell University
1985
BS
Plant Protection
Nanjing Agricultural University
1982

Ziding Feng is a biometrics expert who applies statistical analysis to biological data. Much of his research is focused on biomarker evaluation for cancer risk assessment, early detection, diagnosis and prognosis. For many years, he was principal investigator of the Data Management and Coordinating Center for the National Cancer Institute-funded Early Detection Research Network, or EDRN, a multicenter research collaboration that focuses on biomarker discovery and validation. In that role, he was responsible for coordinating all of EDRN’s research activities, providing logistical support and conducting statistical and computational research for data analysis. Dr. Feng has also acted as lead biostatistician on a number of large, multicenter biomarker trials for cancers of the prostate, liver, lung, colon and esophagus.